# Glycosyn

announced in December 2024 the availability for licensing of its commercial high-titer HMO production strains and IP covering prebiotic, anti-inflammatory and anti-infective uses, with strains validated at large fermentation scale for 2'-FL, LNT, 3'-SL and 6'-SL.

Source: https://en.bioecon.ru/companies/glycosyn/
Updated: 2026-07-05

- Country: United States

## Technologies

- [Human milk oligosaccharides (HMOs)](https://en.bioecon.ru/technology/human-milk-oligosaccharides-hmos/)